LAVAL, QC, Nov. 8, 2018 /CNW/ - Crescita Therapeutics Inc. (TSX: CTX) (Crescita or the Company), a Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, is pleased to announce that it has launched five product innovations in its lead aesthetic skincare brand, Laboratoire Dr Renaud, sold to professional aestheticians and aesthetic schools throughout Canada. The launch events were kicked-off in Montréal, Québec, in mid-September, bringing together the brand's top clients and concluded earlier this week in Vancouver, BC.
The Innovations were launched only six months following the return of Isabelle Villeneuve, an internationally recognized leader in innovation and market intelligence, as head of Strategy, Quality and Innovation. These product innovations come at a time of growing demand for fresh and novel skincare products, especially microbiome-inspired products and dry mask technologies. The innovations offering round off the Laboratoire Dr Renaud portfolio with two Retinol-based products, a gold standard for correcting photoaging as well as the signs of chronological ageing, however, the most notable additions to the portfolio are:
- Lift Jeunesse – Intense Restructuring with MMPE™: An anti-ageing formulation introducing Crescita's patented MMPE technology specifically designed to enhance the penetration of key ingredients deeper into the skin without invasive procedures or abrasive chemicals.
- Triple Lipid Regenerating Youth Care: A hydrating formulation including the skin's three essential lipids (ceramides, cholesterol and fatty acids) with a dominant cholesterol ratio to meet the demands of mature skin. This formulation also includes Ecobiotys®, an award-winning prebiotic of natural origin that specifically rebalances the microbiota1 of mature skin. Crescita is one of the very first companies worldwide to launch a product with Ecobiotys® thanks to its expertise and speed of bringing innovation to market.
- PURE Youth Infuser Dry Mask: In response to high demand for innovative masks, Crescita has become one of the first players in the professional aesthetic spa market to introduce the dry mask technology. Using a third-party patented technology, the dry mask does not necessitate any water; the formula is printed on a piece of textile. The biometric Bio-Vectors release the key active ingredients which are instantly absorbed through the skin.
"Innovation is the driving force behind our team and at each level of our organization, we foster agility and creativity in our people" said Isabelle Villeneuve, Vice-President, Strategy, Quality and Innovation. "We use our deep expertise and know-how to create exciting and innovative products that pave the pathway to differentiating us from our competitors and keep our brands top of mind in an ever-evolving market."
"The launch of these innovations is a testament to our commitment to executing our growth strategy and brings us another step closer to becoming a leader in the Canadian dermo-cosmetic industry. We are enthusiastic and energized by the possibilities that the future holds" said Serge Verreault, President and CEO of Crescita.
The skin's microbiota is the term used to describe the collection of microorganisms that live on our skin. More specifically, it refers to the genomes of all these microbes including bacteria, fungi, protozoa, viruses, and mites living. (Source: www.news-medical.net/life-sciences/Skin-Microbiota.aspx)
About Laboratoire Dr Renaud
The Laboratoire Dr Renaud skincare line is inspired by nature and joins science and aesthetics to develop personalized solutions to address daily skin challenges such as: aging; acne; rosacea; pigmentation; dehydration; sun care and sensitivity. The product line was founded in France in 1947 by Dr. Louis Raymond Renaud, a renowned French dermatologist, and became a Canadian company based in Montreal in 1963. The Laboratoire Dr Renaud skincare products are sold exclusively to professional aestheticians, in spas and aesthetic schools. Innovation and science have been at the heart of the brand since its inception. The products are designed according to the principles of biomimicry which mimic natural processes, thus making them extremely biocompatible with the skin. Crescita owns the trademark rights for the skincare line in North America, certain South American countries and the Pacific Rim as well as the worldwide rights for the formulations.
The MMPE technology uses synergistic combinations of pharmaceutical excipients included on the FDA's Inactive Ingredient Guide for improved topical delivery of active pharmaceutical ingredients (APIs) into or through the skin. The benefits of this technology include the potential for increased penetration of APIs with the possibility of improved efficacy, lower API concentration and/or reduced dosing. Issued U.S. patents provide intellectual property protection through March 6, 2027.
ECOBIOTYS® by Silab is an innovative biomimetic ingredient developed to address skin complexion improvement. Obtained from the yeast Metschnikowia reukaufii, isolated from the nectar of the porcelain flower Hoya carnosa, ECOBIOTYS® specifically rebalances the microbiota of mature skin by reinforcing the immune and mechanical barriers of the skin and acting on the distribution of bacterial communities. The quality of the skin barrier is thereby improved, and the complexion is enhanced. Only a few months after having received the Bronze Award at in-cosmetics Global, ECOBIOTYS® won the Gold Award of the Innovation Zone Best Active Ingredient at in-cosmetics Asia (Bangkok, Thaïland). The honor was awarded by a panel of worldwide experts from the cosmetic industry, this prize distinguishes the development of a new active principle that combines innovation and substantial benefits for the end-users. To find out more about ECOBIOTYS®, please visit https://www.silab.fr/produit-105-ecobiotys_usa.html.
About Crescita Therapeutics Inc.
Crescita (TSX: CTX) is a publicly traded, Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions and diseases and their symptoms. Crescita owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active drugs into or through the skin. For additional information, please visit www.crescitatherapeutics.com.
This Press Release contains "forward-looking statements" within the meaning of applicable securities laws. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company's current beliefs, expectations and assumptions, the future of its business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company's control. Crescita's actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, readers should not rely on any of these forward-looking statements. Important factors that could cause Crescita's actual results and financial condition to differ materially from those indicated in the forward-looking statements include, the risk factors included in Crescita's most recent Annual Information Form dated March 27, 2018 under the heading "Risks Factors", and as described from time to time in the reports and disclosure documents filed by Crescita with Canadian securities regulatory agencies and commissions. These and other factors should be considered carefully, and readers should not place undue reliance on Crescita's forward-looking statements. As a result of the foregoing and other factors, no assurance can be given as to any such future results, levels of activity or achievements and none of Crescita or any other person assumes responsibility for the accuracy and completeness of these forward-looking statements. Any forward-looking statement made by the Company in this Press Release is based only on information currently available to it and speaks only as of the date on which it is made. Except as required by applicable securities laws, Crescita undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
SOURCE Crescita Therapeutics Inc.